FICZ protected against the development of colitis symptoms by decreasing pro-inflammatory cytokine production (IL-17, IL-1β, IL-6, TNF-α, and IFN-γ) and by increasing anti-inflammatory IL-22 production from Th17 cells [18,48,49]. This evidence concerns the gene IFNG and colitis.